Article
GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.
The international journal of neuropsychopharmacology - 1 Oct 2014
Kranzler Henry R, Armeli Stephen, Feinn Richard, Tennen Howard, Gelernter Joel, Covault Jonathan
Abstract excerpt
We (Kranzler et al., 2014) reported that topiramate 200 mg/day reduced heavy drinking days and increased abstinent days in 138 heavy drinkers whose treatment goal was to reduce drinking to safe levels. In that 12-week, placebo-controlled study, we measured drinking using the Timeline Follow-back method at each treatment visit. In addition to the intent-to-treat effects of topiramate, we found that a single...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.